RESEARCH-USE BIOSIMILAR ANTIBODY
Secukinumab
Monoclonal antibody · IgG1
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis.
TARGETIL17A
YMonoclonal antibody
CATALOGSC-BS-189
CATALOG NUMBERSC-BS-189
MOLECULAR WEIGHTApprox. 147.82 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis.
Secukinumab is a recombinant research-use antibody directed against IL17A.